Searching…
Mar 15, 2025 · ANCHOR-1 and ANCHOR-2 are the first large, multinational, phase 3 trials to show the efficacy and safety of the ultra-long-acting anti-IL-5 biological drug depemokimab versus placebo as an add-on treatm...
Oct 31, 2025 · Affordable New Jersey Communities for Homeowners and Renters (ANCHOR) This program offers property tax relief to New Jersey residents who own or rent property in New Jersey as their main home and meet c...
Mar 10, 2022 · Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials.
The efficacy of twice-yearly depemokimab in significantly improving clinically relevant coprimary endpoints was demonstrated in ANCHOR-1/2, while exhibiting a well-tolerated safety profile.
Mar 3, 2025 · ANCHOR-1 (N=271) and ANCHOR-2 (N=257) met their co-primary endpoints, with twice-yearly administration of depemokimab showing clinically meaningful and statistically significant improvements in nasal pol...
ANCHOR-1 and ANCHOR-2 were replicate phase III clinical trials assessing the safety and efficacy of depemokimab in patients with CRSwNP. Both were 52-week, randomised, double-blind, parallel group, placebo controlled,...
Participants presenting with severe NP symptoms defined as symptoms of nasal congestion/blockade/obstruction with moderate or severe severity and loss of smell or rhinorrhea (runny nose) based on clinical assessment b...
GSK is conducting a study to test how safe and effective a medicine called depemokimab is at treating nasal polyps. Depemokimab is a type of medicine called a monoclonal antibody, that works by reducing the number of ...
Wooden Replacement Lids Compatible with Anchor Hocking Glass Containers, 1-Cup Round, 2 Pack Small Business
Mar 6, 2025 · ANCHOR-1 (N=271) and ANCHOR-2 (N=257) met their co-primary endpoints, with twice-yearly administration of depemokimab showing clinically meaningful and statistically significant improvements in nasal pol...
